TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY

被引：0
|
作者：
Bell, J. [1 ]
Galaznik, A. [1 ]
Farrelly, E. [2 ]
Blazer, M. [2 ]
Shih, H-C. [2 ]
Raju, A. [2 ]
Ogbonnaya, A. [2 ]
Eaddy, M. [2 ]
Fram, R. [1 ]
Faller, D. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Xcenda, Palm Harbor, FL USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1196
引用
收藏
页码：491 / 492
页数：2
相关论文
共 50 条
  • [1] SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H. -C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 489 - 489
  • [2] ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H. -C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 486 - 486
  • [3] Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
    Jill A. Bell
    Aaron Galaznik
    Marlo Blazer
    Huai-Che Shih
    Eileen Farrelly
    Augustina Ogbonnaya
    Michael Eaddy
    Robert J. Fram
    Douglas V. Faller
    PharmacoEconomics - Open, 2019, 3 : 237 - 245
  • [4] Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
    Bell, Jill A.
    Galaznik, Aaron
    Blazer, Mario
    Shih, Huai-Che
    Farrelly, Eileen
    Ogbonnaya, Augustina
    Eaddy, Michael
    Fram, Robert J.
    Faller, Douglas, V
    PHARMACOECONOMICS-OPEN, 2019, 3 (02) : 237 - 245
  • [5] Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System
    Moore, Kristin J.
    Engel-Nitz, Nicole M.
    McMahon, Peter
    Beal, Jason
    Jhaveri, Teraneh Z.
    Williamson, Mellissa
    Andrade, Katherine
    Landis, Christina
    Sadek, Islam
    Hogea, Cosmina
    BLOOD, 2023, 142
  • [6] Higher-Risk Myelodysplastic Neoplasms (HR-MDS) Patient Characteristics in a Large, Integrated United States (US) Healthcare System
    Moore, Kristin
    Engel-Nitz, Nicole
    McMahon, Peter
    Beal, Jason
    Jhaveri, Tizzy
    Williamson, Mellissa
    Andrade, Kate
    Landis, Christina
    Hogea, Cosmina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S365 - S365
  • [7] EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Conkling, P.
    Cogle, C. R.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Beach, C.
    Skikne, B. S.
    HAEMATOLOGICA, 2015, 100 : 239 - 239
  • [8] A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting
    Rossetti, James M.
    Choksi, Rushir
    Vasudevan, Anupama
    Blanc, Simon
    Brenneman, Dawn
    Wang, Brandon
    McMahon, Peter
    Beal, Jason
    Jhaveri, Teraneh Z.
    Williamson, Mellissa
    Hogea, Cosmina
    BLOOD, 2023, 142
  • [9] Impact of Transformation to Acute Myeloid Leukemia (AML) on Overall Survival (OS) among Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the United States of America (USA)
    Kota, Vamsi
    Ogbonnaya, Augustina
    Farrelly, Eileen
    Schroader, Bridgette
    Kristo, Fjoralba
    Raju, Aditya
    Dalal, Mehul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S348 - S348
  • [10] Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
    Zeidan, Amer M.
    Al-Kali, Aref
    Borate, Uma
    Cluzeau, Thomas
    DeZern, Amy E.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kobata, Krissy
    Lyons, Roger
    Platzbecker, Uwe
    Sallman, David A.
    Santini, Valeria
    Sanz, Guillermo F.
    Sekeres, Mikkael A.
    Wei, Andrew H.
    Xiao, Zhijian
    Van Hoef, Marlies
    Nourry-Boulot, Claire
    Sadek, Islam
    Ma, Fei
    Iordan, Angelica
    Sabo, John
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S317
12345